Journal
BMJ CASE REPORTS
Volume 15, Issue 4, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/bcr-2021-246264
Keywords
Haematology (incl blood transfusion); Oncology
Categories
Ask authors/readers for more resources
BRAF V600E mutations are rare in patients with multiple myeloma, but they are associated with disease aggressiveness, extramedullary growth frequency, and survival period. The combination therapy of BRAF and MEK inhibitors has shown promising results in refractory MM patients.
BRAF V600E mutations are detected in 3%-10% of patients with multiple myeloma (MM) and are associated with more aggressive disease, higher frequency of extramedullary growth and shorter survival. Monotherapy with the BRAF inhibitor vemurafenib has been disappointing in MM. In patients with BRAF-mutated melanoma, MEK and BRAF inhibition has been a successful approach. Here we describe a very good partial response and possible mechanisms of resistance to a combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in a patient with BRAF V600E-mutant refractory MM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available